* confirmed acute cases of sars-cov-2 infection. * with a medical history of sars, mers virus infection (self-report, on-site inquiry); * fever (axillary temperature \> 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea within 14 days before vaccination (tympanic temperature / temporal artery temperature \>37.5 ℃); * positive urine pregnancy test result. * body temperature axillary ≥ 37.0 ℃ before vaccination（tympanic temperature / temporal artery temperature≥ 37.5 ℃); * with previous severe allergic reactions (such as acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of the inactivated sars-cov-2 vaccine. * with a medical history or a family history of convulsion, epilepsy, encephalopathy or mental illness. * with congenital malformation or developmental disorder, genetic defects, severe malnutrition, etc.; * with known or suspected diseases include acute respiratory diseases (e.g. influenza like illness, acute cough, sore throat), severe cardiovascular diseases, severe liver diseases, severe kidney diseases, uncontrollable hypertension (systolic blood pressure \> 150 mmhg, diastolic blood pressure \> 90 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. * has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; with a history of coagulation dysfunction (such as coagulation factor deficiency, coagulation disease); * with a history of coagulation dysfunction (such as coagulation factor deficiency coagulation disease); * receiving anti-tb therapy. * receiving immune enhancement or inhibitor therapy within 3 months (continuous oral or iv administration for more than 14 days); * vaccinated live attenuated vaccine within 1 month before vaccination and other vaccines within 14 days before vaccination; * received blood products within 3 months before vaccination; * received other investigational drugs within 6 months before vaccination; * other circumstances judged by investigators that were not suitable for participating in this clinical trial.

* confirmed acute cases of sars-cov-2 infection. * with a medical history of sars, mers virus infection (self-report, on-site inquiry); * fever (axillary temperature \> 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea within 14 days before vaccination (tympanic temperature / temporal artery temperature \>37.5 ℃); * positive urine pregnancy test result. * body temperature axillary ≥ 37.0 ℃ before vaccination（tympanic temperature / temporal artery temperature≥ 37.5 ℃); * with previous severe allergic reactions (such as acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of the inactivated sars-cov-2 vaccine. * with a medical history or a family history of convulsion, epilepsy, encephalopathy or mental illness. * with congenital malformation or developmental disorder, genetic defects, severe malnutrition, etc.; * with known or suspected diseases include acute respiratory diseases (e.g. influenza like illness, acute cough, sore throat), severe cardiovascular diseases, severe liver diseases, severe kidney diseases, uncontrollable hypertension (systolic blood pressure \> 150 mmhg, diastolic blood pressure \> 90 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. * has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; with a history of coagulation dysfunction (such as coagulation factor deficiency, coagulation disease); * with a history of coagulation dysfunction (such as coagulation factor deficiency coagulation disease); * receiving anti-tb therapy. * receiving immune enhancement or inhibitor therapy within 3 months (continuous oral or iv administration for more than 14 days); * vaccinated live attenuated vaccine within 1 month before vaccination and other vaccines within 14 days before vaccination; * received blood products within 3 months before vaccination; * received other investigational drugs within 6 months before vaccination; * other circumstances judged by investigators that were not suitable for participating in this clinical trial.

- confirmed acute cases of sars-cov-2 infection. - with a medical history of sars, mers virus infection (self-report, on-site inquiry); - fever (axillary temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea within 14 days before vaccination (tympanic temperature / temporal artery temperature >37.5 ℃); - positive urine pregnancy test result. - body temperature axillary ≥ 37.0 ℃ before vaccination（tympanic temperature / temporal artery temperature≥ 37.5 ℃); - with previous severe allergic reactions (such as acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of the inactivated sars-cov-2 vaccine. - with a medical history or a family history of convulsion, epilepsy, encephalopathy or mental illness. - with congenital malformation or developmental disorder, genetic defects, severe malnutrition, etc.; - with known or suspected diseases include acute respiratory diseases (e.g. influenza like illness, acute cough, sore throat), severe cardiovascular diseases, severe liver diseases, severe kidney diseases, uncontrollable hypertension (systolic blood pressure > 150 mmhg, diastolic blood pressure > 90 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; with a history of coagulation dysfunction (such as coagulation factor deficiency, coagulation disease); - with a history of coagulation dysfunction (such as coagulation factor deficiency coagulation disease); - receiving anti-tb therapy. - receiving immune enhancement or inhibitor therapy within 3 months (continuous oral or iv administration for more than 14 days); - vaccinated live attenuated vaccine within 1 month before vaccination and other vaccines within 14 days before vaccination; - received blood products within 3 months before vaccination; - received other investigational drugs within 6 months before vaccination; - other circumstances judged by investigators that were not suitable for participating in this clinical trial.

- confirmed acute cases of sars-cov-2 infection. - with a medical history of sars, mers virus infection (self-report, on-site inquiry); - fever (axillary temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea within 14 days before vaccination (tympanic temperature / temporal artery temperature >37.5 ℃); - positive urine pregnancy test result. - body temperature axillary ≥ 37.0 ℃ before vaccination（tympanic temperature / temporal artery temperature≥ 37.5 ℃); - with previous severe allergic reactions (such as acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of the inactivated sars-cov-2 vaccine. - with a medical history or a family history of convulsion, epilepsy, encephalopathy or mental illness. - with congenital malformation or developmental disorder, genetic defects, severe malnutrition, etc.; - with known or suspected diseases include acute respiratory diseases (e.g. influenza like illness, acute cough, sore throat), severe cardiovascular diseases, severe liver diseases, severe kidney diseases, uncontrollable hypertension (systolic blood pressure > 150 mmhg, diastolic blood pressure > 90 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; with a history of coagulation dysfunction (such as coagulation factor deficiency, coagulation disease); - with a history of coagulation dysfunction (such as coagulation factor deficiency coagulation disease); - receiving anti-tb therapy. - receiving immune enhancement or inhibitor therapy within 3 months (continuous oral or iv administration for more than 14 days); - vaccinated live attenuated vaccine within 1 month before vaccination and other vaccines within 14 days before vaccination; - received blood products within 3 months before vaccination; - received other investigational drugs within 6 months before vaccination; - other circumstances judged by investigators that were not suitable for participating in this clinical trial.